IDX184 Articles
New briefs on Pfizer interest in Protalix; Novo Nordisk warning letter; Hemispherx' Ampligen; and Idenix' hep C program
6 February 2013
Showing 1-2 of 2 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
